BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Metaraminol

A sympathomimetic agent that acts predominantly at alpha-1 adrenergic receptors. It has been used primarily as a vasoconstrictor in the treatment of HYPOTENSION.

299+ PubMed studies analyzed · 15 RCTs · Evidence Score: 46.8

Research Domains

Metaraminol has been studied across 16 research domains including 🧠 Focus & Attention, ❤️ Cardiovascular, 🫘 Kidney, 🌤️ Mood & Depression, 🫁 Liver & Detox. The primary research focus is 🧠 Focus & Attention with 36% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Metaraminol, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Aztreonam
4 shared targets
Pinacidil
4 shared targets
Midodrine
4 shared targets
Modafinil
4 shared targets
Sulfadoxine
4 shared targets
Felbamate
4 shared targets
idebenone
3 shared targets
Nateglinide
4 shared targets
Leuprolide
4 shared targets
Dexamethasone
4 shared targets
Loading evidence profile...

This evidence profile for Metaraminol is generated deterministically from 299 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.